Related Experiment Videos
Intravenous immunoglobulin in rheumatic disease
L W Klassen1, L H Calabrese, R M Laxer
1University of Nebraska Medical Center, Omaha, USA.
Rheumatic Diseases Clinics of North America
|February 1, 1996
Summary
Intravenous immunoglobulin (IVIG) preparations can now be administered in large doses to increase immunoglobulin levels. Studies show IVIG effectively treats thrombocytopenia and autoimmune symptoms in various patients.
Area of Science:
- Immunology
- Hematology
- Autoimmune Diseases
Background:
- Commercial intravenous immunoglobulin (IVIG) preparations have been available since 1981.
- IVIG can be administered in significant quantities to elevate serum immunoglobulin levels.
- Elevated immunoglobulin levels are observed in both antibody-deficient states and individuals with normal immunoglobulin levels.
Purpose of the Study:
- To investigate the therapeutic efficacy of intravenous immunoglobulin preparations.
- To assess the impact of IVIG on thrombocytopenia and autoimmune symptoms.
Main Methods:
- Administration of commercial IVIG preparations.
- Observation of serum immunoglobulin level changes.
- Clinical assessment of thrombocytopenia and autoimmune symptoms in pediatric and adult patients.
Main Results:
- A case report showed dramatic improvement in thrombocytopenia in a child with agammaglobulinemia after IVIG use for infections.
- Further studies indicated therapeutic efficacy of IVIG in controlling autoimmune symptoms.
- IVIG administration led to elevated serum immunoglobulin levels in treated patients.
Conclusions:
- Intravenous immunoglobulin preparations are effective in managing thrombocytopenia, particularly in antibody-deficient states.
- IVIG demonstrates therapeutic benefits in controlling autoimmune symptoms.
- The widespread availability and administration of IVIG have opened new avenues for treating immune-related disorders.